Betrixaban for prevention of venous thromboembolism in acute medically ill patients.

Eur Heart J Suppl · 2018 · PMC6016607 · PMID 29977165

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

did not reach statistical significanceP = 0.054so close (0.05 < p ≤ 0.1)

When first analysed by the clinical research organization (CRO), the primary efficacy outcome occurred in 6.9% of the betrixaban group and 8.5% of the enoxaparin group in Cohort 1, and this difference did not reach statistical significance [relative risk (RR) 0.81; 95% confidence interval (CI) 0.65–1.00; P = 0.054] ( Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.